DBV Technologies grants CEO Daniel Tassé 4.06M PSUs tied to FDA approval of Viaskin Peanut

DBV Technologies S.A.

4,060,000 PSUs awarded to CEO; vesting conditioned on FDA approval of Viaskin Peanut BLA.
First FDA approval of VP (any age) triggers vesting of 2,900,000 PSUs; second approval for a different indication/age triggers 1,160,000 PSUs.
Single BLA covering both age groups deems all performance conditions satisfied.
Vested shares delivered in four equal installments starting July 1, 2028 through January 1, 2030.
PSUs canceled if performance conditions not met by July 1, 2028; continued employment required.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.